Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease.
Biomarkers
Diagnostic
Neurofilament light chain
Plasma
Sporadic Creutzfeldt-Jakob disease
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
11
02
2022
accepted:
18
05
2022
pubmed:
19
6
2022
medline:
25
8
2022
entrez:
18
6
2022
Statut:
ppublish
Résumé
Biomarkers are becoming increasingly important for the differential diagnosis of neurodegenerative diseases. Previous observations indicated neurofilament light chain (NfL) as a potential blood-based biomarker for sporadic Creutzfeldt-Jakob disease (sCJD). Here, we investigated the stability, inter-assay/intra-assay variation and the regulation of NfL levels in CSF and plasma in a large cohort of sCJD patients by using a single-molecule array (SIMOA). We defined cutoffs for an accurate diagnosis and measured plasma NfL level in prion-infected mice models at different time points to identify the potential dynamics throughout the disease. Our analyses confirmed CSF and plasma NfL as stable and consistent marker for sCJD. Receiver operating characteristic (ROC) curve analysis showed an AUC of 0.92-0.93 to distinguish sCJD from control groups. Newly defined cutoffs revealed good diagnostic accuracies of CSF and plasma NfL, indicated by a sensitivity of 80-83.5% and a specificity of 87.4-91%. Studies on two humanized prion-infected mice lines (Tg340-PRNP 129MM and Tg361-PRNP 129VV) revealed increased plasma NfL levels in a late pre-clinical or very early clinical stage between 120-150 days post-inoculation. In conclusion, our work supports the potential use of CSF and plasma NfL as a very early biomarker in sCJD diagnostic with good diagnostic accuracies.
Identifiants
pubmed: 35716271
doi: 10.1007/s12035-022-02891-7
pii: 10.1007/s12035-022-02891-7
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
Prions
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Subventions
Organisme : Fundació La Marató de TV3
ID : 201821-30
Organisme : Alzheimer Forschung Initiative
ID : 20026
Organisme : Robert Koch-Institute through funds of the Federal Ministry of Health
ID : 1369-341
Organisme : CJD Foundation
ID : Implementation of a blood-based biomarker test for sporadic Creutzfeldt-Jakob in clinical practice
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Prusiner SB (1998) Prions. Proc Natl Acad Sci 95:13363–13383. https://doi.org/10.1073/PNAS.95.23.13363
doi: 10.1073/PNAS.95.23.13363
pubmed: 9811807
pmcid: 33918
Otto M, Wiltfang J, Cepek L et al (2002) Tau protein and 14–3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58:192–197. https://doi.org/10.1212/wnl.58.2.192
doi: 10.1212/wnl.58.2.192
pubmed: 11805244
Cramm M, Schmitz M, Karch A et al (2016) Stability and reproducibility underscore utility of RT-QuIC for diagnosis of Creutzfeldt-Jakob disease. Mol Neurobiol. https://doi.org/10.1007/s12035-015-9133-2
doi: 10.1007/s12035-015-9133-2
pubmed: 25823511
Schmitz M, Cramm M, Llorens F et al (2016) The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases. Nat Protoc. https://doi.org/10.1038/nprot.2016.120
doi: 10.1038/nprot.2016.120
pubmed: 27735933
Schmitz M, Ebert E, Stoeck K et al (2016) Validation of 14–3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic. Mol Neurobiol 53:2189–2199. https://doi.org/10.1007/s12035-015-9167-5
doi: 10.1007/s12035-015-9167-5
pubmed: 25947081
Sanchez-Juan P, Green A, Ladogana A et al (2006) CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67:637–643. https://doi.org/10.1212/01.wnl.0000230159.67128.00
doi: 10.1212/01.wnl.0000230159.67128.00
pubmed: 16924018
Zerr I, Villar-Piqué A, Hermann P et al (2021) Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res Ther 13:86. https://doi.org/10.1186/s13195-021-00815-6
doi: 10.1186/s13195-021-00815-6
pubmed: 33883011
pmcid: 8059191
Steinacker P, Blennow K, Halbgebauer S et al (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep 6 https://doi.org/10.1038/SREP38737
Thompson AGB, Luk C, Heslegrave AJ et al (2018) Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry 89:955–961. https://doi.org/10.1136/JNNP-2017-317793
doi: 10.1136/JNNP-2017-317793
pubmed: 29487167
Vallabh SM, Minikel EV, Schreiber SL, Lander ES (2020) Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurol 19:361–368. https://doi.org/10.1016/S1474-4422(19)30403-X
doi: 10.1016/S1474-4422(19)30403-X
pubmed: 32199098
Rissin DM, Kan CW, Campbell TG et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. https://doi.org/10.1038/nbt.1641
doi: 10.1038/nbt.1641
pubmed: 20495550
pmcid: 2919230
Windl O, Giese A, Schulz-Schaeffer W et al (1999) Molecular genetics of human prion diseases in Germany. Hum Genet 105:244–252. https://doi.org/10.1007/s004399900124
doi: 10.1007/s004399900124
pubmed: 10987652
Who (1998) Human transmissible spongiform encephalopathies. Wkly Epidemiol Rec 73:361–365
Zerr I, Kallenberg K, Summers DM et al (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132:2659–2668. https://doi.org/10.1093/brain/awp191
doi: 10.1093/brain/awp191
pubmed: 19773352
pmcid: 2759336
Hermann P, Appleby B, Brandel J-P et al (2021) Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 20:235–246. https://doi.org/10.1016/S1474-4422(20)30477-4
doi: 10.1016/S1474-4422(20)30477-4
pubmed: 33609480
pmcid: 8285036
Who (2003) WHO Manual for Surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease. Communicable disease surveillance and response. World Health Organisation Genova, 51–59
Zerr I, Schulz-Schaeffer WJ, Giese A et al (2000) Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol 48:323–329
doi: 10.1002/1531-8249(200009)48:3<323::AID-ANA6>3.0.CO;2-5
Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementiaassociated with Parkinson' disease. Mov Disord 22(12):1689–707
McKeith IG, Boeve BF, DIckson D et al (2017) Diagnosis and management of dementia with Lewy bodies. Neurology 89(1):88–100
Gilman S, Low PA, Quinn N et al (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163:94–98. https://doi.org/10.1016/S0022-510X(98)00304-9
doi: 10.1016/S0022-510X(98)00304-9
pubmed: 10223419
Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676. https://doi.org/10.1212/01.wnl.0000324625.00404.15
doi: 10.1212/01.wnl.0000324625.00404.15
pubmed: 18725592
pmcid: 2676993
Skrobot OA, Black SE, Chen C et al (2018) Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement 14:280–292. https://doi.org/10.1016/j.jalz.2017.09.007
doi: 10.1016/j.jalz.2017.09.007
pubmed: 29055812
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005
doi: 10.1016/j.jalz.2011.03.005
pubmed: 21514250
pmcid: 3312024
Padilla D, Béringue V, Espinosa JC et al (2011) Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog 7:e1001319. https://doi.org/10.1371/journal.ppat.1001319
doi: 10.1371/journal.ppat.1001319
pubmed: 21445238
pmcid: 3060172
Fernández-Borges N, Espinosa JC, Marín-Moreno A et al (2017) Protective effect of Val(129)-PrP against bovine spongiform encephalopathy but not variant Creutzfeldt-Jakob disease. Emerg Infect Dis 23:1522–1530. https://doi.org/10.3201/eid2309.161948
doi: 10.3201/eid2309.161948
pubmed: 28820136
pmcid: 5572891
Youden WJ (1950) Index for rating diagnostic tests. Cancer 3:32–35. https://doi.org/10.1002/1097-0142(1950)3:1%3c32::aid-cncr2820030106%3e3.0.co;2-3
doi: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
pubmed: 15405679
Canaslan S, Schmitz M, Villar-Piqué A et al (2021) Detection of cerebrospinal fluid neurofilament light chain as a marker for alpha-synucleinopathies. Front Aging Neurosci 13:717930. https://doi.org/10.3389/fnagi.2021.717930
doi: 10.3389/fnagi.2021.717930
pubmed: 34630068
pmcid: 8493247
Schmitz M, Canaslan S, Villar-Piqué A et al (2021) Validation of plasma neurofilament light chain as a marker for α-synucleinopathies. Mov Disord 36:2701–2703
doi: 10.1002/mds.28724
Altmann P, Ponleitner M, Rommer PS et al (2021) Seven day pre-analytical stability of serum and plasma neurofilament light chain. Sci Rep 11:11034. https://doi.org/10.1038/s41598-021-90639-z
doi: 10.1038/s41598-021-90639-z
pubmed: 34040118
pmcid: 8154890
Gaetani L, Blennow K, Calabresi P et al (2019) Neurofilament light chain as a biomarker in neurological disorders. Neurol Neurosurg Psychiatry 90(8):870–881
doi: 10.1136/jnnp-2018-320106
Khalil M, Pirpamer L, Hofer E et al (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. https://doi.org/10.1038/s41467-020-14612-6
doi: 10.1038/s41467-020-14612-6
pubmed: 33149115
pmcid: 7642387
Abu-Rumeileh S, Capellari S, Stanzani-Maserati M et al (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther 10:3. https://doi.org/10.1186/s13195-017-0331-1
doi: 10.1186/s13195-017-0331-1
pubmed: 29368621
pmcid: 5784714
Kanata E, Golanska E, Villar-Piqué A et al (2019) Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease. J Clin Neurosci Off J Neurosurg Soc Australas 60:124–127. https://doi.org/10.1016/j.jocn.2018.09.031
doi: 10.1016/j.jocn.2018.09.031
Zerr I, Schmitz M, Karch A et al (2018) Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement 14:751–763. https://doi.org/10.1016/j.jalz.2017.12.008
doi: 10.1016/j.jalz.2017.12.008
pubmed: 29391125
Schmitz M, Villar-Piqué A, Llorens F et al (2019) Cerebrospinal fluid total and phosphorylated α-synuclein in patients with Creutzfeldt-Jakob disease and synucleinopathy. Mol Neurobiol. https://doi.org/10.1007/s12035-018-1313-4
doi: 10.1007/s12035-018-1313-4
pubmed: 31848935
Thompson AGB, Anastasiadis P, Druyeh R et al (2021) Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Mol Psychiatry 26:5955–5966. https://doi.org/10.1038/S41380-021-01045-W
doi: 10.1038/S41380-021-01045-W
pubmed: 33674752
pmcid: 8758487
Zerr I (2009) Therapeutic trials in human transmissible spongiform encephalo-pathies: recent advances and problems to address. Infect Disord Drug Targets 9:92–99. https://doi.org/10.2174/1871526510909010092
doi: 10.2174/1871526510909010092
pubmed: 19200019
Hermann P, Canaslan S, Villar-Piqué A et al (2022) Plasma neurofilament light chain as a biomarker for fatal familial insomnia. Eur J Neurol. https://doi.org/10.1111/ENE.15302
doi: 10.1111/ENE.15302
pubmed: 35524506